Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
ECYT's Cash to Debt is ranked higher than
84% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. ECYT: No Debt )
ECYT' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: No Debt

Equity to Asset 0.93
ECYT's Equity to Asset is ranked higher than
98% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. ECYT: 0.93 )
ECYT' s 10-Year Equity to Asset Range
Min: 0.45   Max: 0.93
Current: 0.93

0.45
0.93
F-Score: 5
Z-Score: 10.52
M-Score: -0.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -28.27
ECYT's Operating margin (%) is ranked higher than
50% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. ECYT: -28.27 )
ECYT' s 10-Year Operating margin (%) Range
Min: -20228.8   Max: -28.27
Current: -28.27

-20228.8
-28.27
Net-margin (%) -27.80
ECYT's Net-margin (%) is ranked higher than
51% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. ECYT: -27.80 )
ECYT' s 10-Year Net-margin (%) Range
Min: -21220.94   Max: -27.8
Current: -27.8

-21220.94
-27.8
ROE (%) -20.44
ECYT's ROE (%) is ranked higher than
50% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. ECYT: -20.44 )
ECYT' s 10-Year ROE (%) Range
Min: -35.75   Max: -17.37
Current: -20.44

-35.75
-17.37
ROA (%) -11.07
ECYT's ROA (%) is ranked higher than
52% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. ECYT: -11.07 )
ECYT' s 10-Year ROA (%) Range
Min: -94.72   Max: -8.08
Current: -11.07

-94.72
-8.08
ROC (Joel Greenblatt) (%) -477.78
ECYT's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. ECYT: -477.78 )
ECYT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3487.09   Max: -477.78
Current: -477.78

-3487.09
-477.78
EBITDA Growth (%) -72.10
ECYT's EBITDA Growth (%) is ranked lower than
54% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ECYT: -72.10 )
ECYT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -70.2
Current: -72.1

EPS Growth (%) -71.60
ECYT's EPS Growth (%) is ranked lower than
53% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ECYT: -71.60 )
ECYT' s 10-Year EPS Growth (%) Range
Min: 0   Max: -70.5
Current: -71.6

» ECYT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ECYT Guru Trades in Q3 2013

RS Investment Management 480,300 sh (New)
Jim Simons 70,400 sh (+165.66%)
» More
Q4 2013

ECYT Guru Trades in Q4 2013

Paul Tudor Jones 16,744 sh (New)
RS Investment Management 510,400 sh (+6.27%)
Jim Simons Sold Out
» More
Q1 2014

ECYT Guru Trades in Q1 2014

Steven Cohen 23,228 sh (New)
Paul Tudor Jones 50,000 sh (+198.61%)
RS Investment Management 470,800 sh (-7.76%)
» More
Q2 2014

ECYT Guru Trades in Q2 2014

Jim Simons 210,200 sh (New)
RS Investment Management Sold Out
Paul Tudor Jones 37,400 sh (-25.2%)
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-06-30 Sold Out 0.07%$3.8 - $8.35 $ 6.985%0
George Soros 2012-03-31 Add 53.85%0.03%$3.36 - $5.89 $ 6.9888%1000000
George Soros 2011-12-31 Add 766.67%0.1%$3.06 - $11.3 $ 6.98-22%650000
George Soros 2011-09-30 New Buy0.01%$9.36 - $14.65 $ 6.98-41%75000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.80
ECYT's P/E(ttm) is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. ECYT: 25.80 )
ECYT' s 10-Year P/E(ttm) Range
Min: 23.07   Max: 26.2
Current: 25.8

23.07
26.2
P/B 1.30
ECYT's P/B is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ECYT: 1.30 )
ECYT' s 10-Year P/B Range
Min: 0.97   Max: 13.04
Current: 1.3

0.97
13.04
P/S 2.68
ECYT's P/S is ranked higher than
70% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ECYT: 2.68 )
ECYT' s 10-Year P/S Range
Min: 2.43   Max: 1100
Current: 2.68

2.43
1100
EV-to-EBIT 11.83
ECYT's EV-to-EBIT is ranked higher than
92% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. ECYT: 11.83 )
ECYT' s 10-Year EV-to-EBIT Range
Min: 11.4   Max: 13.9
Current: 11.83

11.4
13.9
Current Ratio 8.42
ECYT's Current Ratio is ranked higher than
92% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. ECYT: 8.42 )
ECYT' s 10-Year Current Ratio Range
Min: 1.26   Max: 25.59
Current: 8.42

1.26
25.59
Quick Ratio 8.42
ECYT's Quick Ratio is ranked higher than
93% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. ECYT: 8.42 )
ECYT' s 10-Year Quick Ratio Range
Min: 1.26   Max: 25.59
Current: 8.42

1.26
25.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.80
ECYT's Price/Net Cash is ranked higher than
98% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ECYT: 2.80 )
ECYT' s 10-Year Price/Net Cash Range
Min: 1.22   Max: 32.02
Current: 2.8

1.22
32.02
Price/Net Current Asset Value 2.70
ECYT's Price/Net Current Asset Value is ranked higher than
98% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ECYT: 2.70 )
ECYT' s 10-Year Price/Net Current Asset Value Range
Min: 1.22   Max: 21.88
Current: 2.7

1.22
21.88
Price/Tangible Book 1.40
ECYT's Price/Tangible Book is ranked higher than
92% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. ECYT: 1.40 )
ECYT' s 10-Year Price/Tangible Book Range
Min: 1.19   Max: 11.02
Current: 1.4

1.19
11.02
Price/Median PS Value 0.30
ECYT's Price/Median PS Value is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. ECYT: 0.30 )
ECYT' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 37.6
Current: 0.3

0.25
37.6
Price/Graham Number 1.10
ECYT's Price/Graham Number is ranked higher than
93% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.75 vs. ECYT: 1.10 )
ECYT' s 10-Year Price/Graham Number Range
Min: 1.07   Max: 1.07
Current: 1.1

Earnings Yield (Greenblatt) 8.00
ECYT's Earnings Yield (Greenblatt) is ranked higher than
86% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. ECYT: 8.00 )
ECYT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.2   Max: 8.8
Current: 8

7.2
8.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:9EY.Germany
Endocyte, Inc. is a biopharmaceutical Company. It targets therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnose.
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
comment on ECYT Mar 06 2013 
Merck: Ready to Rise on New Drugs Apr 18 2012 
3.13 Jan 30 2012 
Lots of insider trad Jan 13 2012 

More From Other Websites
Endocyte to Present at the Baird 2014 Health Care Conference Aug 27 2014
ENDOCYTE 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General... Aug 22 2014
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving... Aug 20 2014
Lifshitz & Miller Law Firm Announces Investigation of Endocyte, Inc., EVOQ Properties Inc., Fortegra... Aug 18 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 in Endocyte, Inc. to... Aug 18 2014
ENDOCYTE INC Financials Aug 15 2014
ENDOCYTE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Aug 14 2014
Endocyte Scientific Team Selected to Receive 2015 George and Christine Sosnovsky Award for Cancer... Aug 14 2014
Endocyte Scientific Team Selected to Receive 2015 George and Christine Sosnovsky Award for Cancer... Aug 14 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Endocyte, Inc.... Aug 13 2014
ENDOCYTE INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
Endocyte Announces Presentations at the 248th American Chemical Society National Meeting &... Aug 07 2014
Endocyte Announces Presentations at the 248th American Chemical Society National Meeting &... Aug 07 2014
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Aug 07 2014
Valeant Pharmaceuticals Slumps: VRX Falls 5.3% in Session Aug 06 2014
Endocyte to Present at Wedbush 2014 Life Sciences Management Access Conference Aug 05 2014
Endocyte to Present at Wedbush 2014 Life Sciences Management Access Conference Aug 05 2014
Lieff Cabraser Announces Class Action Litigation Against Endocyte, Inc. - ECYT Aug 01 2014
Endocyte Inc Stock Upgraded (ECYT) Aug 01 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Endocyte, Inc. To... Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK